勵晶太平洋:2023年年報
Regent Pacific Reports Profitable Year in 2023
Crystal Pacific (00575) announced 2023 results. Shareholders' share loss of approximately US$2.55 million decreased by 31.24% year over year
Crystal Pacific (00575) announced its 2023 results, with revenue of US$291,000, an increase of 1.55 times over the previous year...
REGENT PACIFIC: Audited Final Results for the Year Ended 31 December 2023
Li Jing Pacific (00575.HK) plans to sell 25% of Qujing Dawei's gas supply shares for 8 million yuan
Gelonghui March 25 | Li Jing Pacific (00575.HK) announced that on March 24, 2024, the company's indirect wholly-owned subsidiary Amerinvest Coal Industry Holding Company Limited (as the seller) entered into a sales agreement with Qujing Heijin Energy Co., Ltd. (as the buyer). According to this, the seller conditionally agreed to sell and the buyer conditionally agreed to buy 25% of the seller's shares in Qujing Dawei Coking Gas Supply Co., Ltd. (target company), after deducting any taxes in China After that, the cost was RMB 8,
Crystal Pacific (00575.HK) will hold a board meeting on March 27 to approve the annual results
On March 15, Ge Longhui Pacific (00575.HK) announced that the company will hold a board meeting on March 27, 2024 to approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023, and to consider the payment of a final dividend (if any).
Crystal Pacific (00575.HK) Profit Alert: Equity holders are expected to account for losses of US$22 million to US$25 million in 2023
Glonghui, Feb. 20, 丨 Li Jing Pacific (00575.HK) announced that the Group expects to record losses attributable to equity holders of the Company from approximately US$22 million (or approximately HK$171.6 million) to approximately US$171.6 million (or approximately HK$195 million) for the year ended 31 December 2022 (the “corresponding period”), reflecting a significant reduction in losses due to the year ended 31 December 2022 (the “corresponding period”).
REGENT PACIFIC: 2023 Interim Report
REGENT PACIFIC: Unaudited Interim Results for the Six Months Ended 30 June 2023
Exciting Pacific (00575.HK) plans to hold a board meeting on August 29 to approve interim results
GLONGHUI, August 17, | Exciting Pacific (00575.HK) announced that the company will hold a board meeting on August 29, 2023 (Tuesday) to approve (among others) the company's and its subsidiaries' interim results and announcements for the six months ended June 30, 2023, and consider the payment of interim dividends (if any).
REGENT PACIFIC: Date of Board Meeting
Lijing Pacific (00575): Ihsan Al Chalabi Appointed as Independent Non-Executive Director
According to the Zhitong Finance App, Lijing Pacific (00575) issued an announcement effective August 15, 2023: Julie Oates has resigned as an independent non-executive director, chairman and member of the Audit Committee, and a member of the Nomination Committee and the Remuneration Committee. Ihsan Al Chalabi has been appointed as an independent non-executive director. Chen Hongjun has been appointed as Chairman of the Audit Committee, a member of the Nomination Committee and the Remuneration Committee respectively.
REGENT PACIFIC: Profit Warning
Endurance RP Changes Name to Regent Pacific Group
Endurance RP's (HKG:0575) has changed its name to Regent Pacific Group Limited, according to a Thursday filing. The biopharmaceutical investment company's stock short name will also be changed to REGE
Shoukang Group (00575) appoints Luo Shenmei as auditor
According to the Zhitong Finance App, Shoukang Group (00575) announced that Hong Kong Lixin Dehao has resigned as the company's external auditor, effective June 21, 2023, and Luo Shen Mei Certified Public Accountants Limited has been appointed as an auditor, effective from June 21, 2023. On the recommendation of the Audit Committee, the Board of Directors decided to appoint Luo Shenmei as the new auditor, effective June 21, 2023, to fill the temporary vacancy after Hong Kong Lixin Dehao's resignation. The term of office is until the end of the company's next annual general meeting of shareholders, but only by shareholders in the form of an ordinary resolution in accordance with the company's articles of association.
ENDURANCE RP To Carry Out 1-for-20 Reverse Stock Split On June 5th, 2023
June 2nd - $ENDURANCE RP(00575.HK)$ is about to implement a 1-for-20 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from June 5th, 2023.$ENDURANCE RP(00575.HK)$
Shoukang Group: 2022 Annual Report
Shoukang Group: Hope Senstenda can help more than 170 million patients in China ten years after launch
Gelonhui, April 19, 丨 Shoukang Group (0575.HK) announced on the 17th that its commercial strategic partner Jiangsu Wanbang Pharmaceutical has completed the third phase of the Senstend treatment of premature ejaculation in China. Jamie Gibson, CEO of Shoukang Group, indicated that Senstend is expected to help about 9 million patients in China in its first year of launch, and is expected to grow to over 170 million patients in the tenth year. The study achieved excellent results, reaching the incubation time for vaginal ejaculation (“incubation time for vaginal ejaculation”) and the premature ejaculation index (“premature ejaculation”)
Endurance RP Partner Achieves Co-Primary Endpoints in Trial for Premature Ejaculation Drug
07:10 AM EDT, 04/18/2023 (MT Newswires) -- A phase 3 study of Senstend by Endurance RP's (HKG:0575)'s commercial strategic partner Wanbang Biopharmaceutical has achieved all four co-primary endpoints.
Shoukang Group (00575.HK): Fortacin/Senstenda Phase III data is impressive, with good tolerability and safety
On April 17, 2023, Shoukang Group (00575.HK) is pleased to announce that its commercial strategic partner Jiangsu Wanbang Biochemical Group Co., Ltd. (“Jiangsu Wanbang Pharmaceutical”) has completed the third phase of a double-blind placebo control study on Senstend's treatment of premature ejaculation in China. The study achieved excellent results, reaching all four common main endpoints: the incubation time for vaginal ejaculation (“incubation time for vaginal ejaculation”), the premature ejaculation index (“premature ejaculation index”), ejaculation control, exponential satisfaction of premature ejaculation, and premature ejaculation index problems. Compared to baseline and placebo, S
No Data